drugset / Trial / NCT00358813

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

NCT00358813

Phase 1 Completed 18 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate how subjects with mild or moderate kidney problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.

Timeline

Start
2006-09-08
Primary completion
2008-08-22
Completion
2008-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 100 mg Oral

Indications

No indication recorded.